SCLEROCYSTIC OVARIES: CURRENT APPROACHES TO THE PROBLEM
https://doi.org/10.17749/2313-7347.2017.11.2.057-068
Abstract
The review addresses the current concepts on polycystic ovary syndrome (PCOS), including the key elements of PCOS etiology, pathogenesis, and epidemiology. The major clinical manifestations, diagnostic standards at early and later stages, treatment regimens, and novel research are also discussed. Despite a lot of research conducted in Russia and elsewhere, many aspects of PCOS remain to be clarified. It is hoped that by introducing recent innovations we can improve medical and instrumental diagnostics, treatment and prevention of PCOS.
About the Authors
A. G. Solopova
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Solopova Antonina Grigorievna - MD, Professor, Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991.
A. D. Makatsariya
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Makatsariya Aleksandr Davidovich - MD, corresponding member of Russian Academy of Sciences, Professor, Head of Department of Obstetrics and Gynecology, Faculty of Preventive Medicine
Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991.
A. E. Solopova
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Solopova Alina Evgenievna - PhD, Assistant Professor, Department of Radiation Diagnostics and Radiation Therapy, Faculty of Internal Diseases
Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991.
O. V. Nikiforova
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Nikiforova Olga Valerievna - 5th year student, Faculty of Pediatrics aculty of Internal Diseases
Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991.
References
1. Khayrutdinova M.R., Egamberdieva L.D. Questions of management of patients with ovarian formations. [Voprosy vedeniya pacientov s ovarial'nymi obrazovaniyami]. Prakticheskaya medicina. 2015; 4-1: 191-7 (in Russian).
2. Shestakova I.G., Ryabinkina LS. PCOS: a new view on problem [Ed. V.E. Radzinsky]. News bulletin. [SPKYA: novyj vzglyad na problemu [Pod red. V.E. Radzinskogo]. Informacionnyj byulleten]. Status Praesens. 2015. 24 s (in Russian).
3. Barthelmess E.K., Naz R.K. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014; 6: 104-19.
4. Gulammakhmudova D.V. Clinical course of polycystic ovary syndrome in women of reproductive age. [Klinicheskoe techenie sindroma polikistoza yaichnikov u zhenshchin reproduktivnogo vozrasta]. Vestnik RGMU. 2015; 2: 32-3 (in Russian).
5. Johansson J., Stener-Victorin E. Polycystic Ovary Syndrome: Effect and Mechanisms of Acupuncture for Ovulation Induction. Evid Based Complement Alternat Med. 2013. 2013: 762615. DOI: 10.1155/2013/762615.
6. Ishchenko A.I., Agadzhanyan E.S., Ishchenko A.A., Gorbenko O.Yu. Modern approaches to treatment of Stein-Levental syndrome. [Sovremennye podkhody v lechenii sindroma Shteina-Leventalya]. Arkhiv akusherstva i ginekologii im. V.F. Snegireva. 2015; 2 (4): 20-5 (in Russian).
7. Mahalingaiah S., Diamanti-Kandarakis E. Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets. 2015; 19 (11): 1561-1574. DOI: 10.1517/14728222.2015.1101067.
8. Palomba S., Santagni S., Falbo A., La Sala G.B. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015; 7: 745-63. DOI: 10.2147/IJWH.S70314.
9. Madyanov I.V., Madyanova T.S. Polycystic ovary syndrome in adolescent girls as a risk factor for cardiovascular disease. [Sindrom polikistoznykh yaichnikov u devochek-podrostkov kak faktor riska serdechno-sosudistykh zabolevanii]. Terapevt. 2012; 5: 34-7 (in Russian).
10. Randeva H.S., Tan B.K., Weickert M.O., Lois K., Nestler J.E., Sattar N. et al. Cardiometabolic Aspects of the Polycystic Ovary Syndrome. Endocr Rev. 2012; 33 (5): 812-41. DOI: 10.1210/er.2012-1003.
11. Solopova A.G., Solopova A.E., Chashchin A.A., Makatsariya A.D. Modern views on the pathogenesis and possibilities of diagnosis of epithelial ovarian cancer. [Covremennye vzglyady na patogenez i vozmozhnosti diagnostici epitelial'nogo raka aichnikov]. Akusherstvo, ginekologiya i reproduktsiya. 2016; 10 (1): 75-83 (in Russian).
12. Gavrailova D. Diabetes type 2 and polycystic ovary syndrome (PCOS). [Diabet 2-go tipa i sindrom polikistoznykh yaichnikov (SPKYa)]. Vestnik po pedagogike i psikhologii Yuzhnoi Sibiri. 2014; 3: 60-73 (in Russian).
13. Dumesic D.A., Oberfield S.E., Stener-Victorin E., Marshall J.C., Laven J.S., Legro R.S. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015; 36 (5): 487-525. DOI: 10.1210/er.2015-1018.
14. Rojas J., Chavez-Castillo M., Bermidez V. The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus. Int J Reprod Med. 2014; 2014: 797681. DOI: 10.1155/2014/797681.
15. Polycystic ovary syndrome: a guide for doctors [Ed. I.I. Dedov, G.A. Melnichenko]. [Sindrom polikistoznykh yaichnikov: rukovodstvo dlya vrachei. [Pod red. I.I. Dedova, G.A. Mel'nichenko]. Moskva: MIA, 2009. 368 s (in Russian).
16. Kamilova N.M., Mastieva E.A. Evaluating of treatment effectiveness of polycystic ovary syndrome according to the echographic study. [Otsenka effektivnosti lecheniya sindroma polikistoznykh yaichnikov po dannym ekhograficheskogo issledovaniya]. Nauchnye vedomosti. Seriya Meditsina. Farmatsiya. 2014; 18 (189): 87-92 (in Russian).
17. Agapova S., Cameo T., Sopher A.B., Oberfield S.E. Diagnosis and Challenges of Polycystic Ovary Syndrome in Adolescence. Semin Reprod Med. 2014; 32 (3): 194-201. DOI: 10.1055/s-0034-1371091.
18. Clark N., Podolski A.J., Brooks E.D., Chizen D.R., Pierson R.A., Lehotay D.C., Lujan М.Е. Prevalence of Polycystic Ovary Syndrome Phenotypes Using Updated Criteria for Polycystic Ovarian Morphology: An Assessment of Over 100 Consecutive Women Self-reporting Features of Polycystic Ovary Syndrome. Reprod Sci. 2014; 21 (8): 1034-43. DOI: 10.1177/1933719114522525.
19. Mamedalieva N.M., Grushevskii V.E., Suyumbaeva G.M., Apselenova M.K. Modern aspects of polycystic ovary syndrome (literature review). [Sovremennye aspekty sindroma polikistoznykh yaichnikov (obzor literatury)]. Vestnik Kazakhskogo Natsional'nogo meditsinskogo universiteta. 2015; 2: 23-7 (in Russian).
20. Anderson A.D., Solorzano C.M., McCartney C.R. Childhood Obesity and Its Impact on the Development of Adolescent PCOS. Semin Reprod Med. 2014; 32 (3): 202-13. DOI: 10.1055/s-0034-1371092.
21. Tehrani F., Simbar M., Tohidi M., Hosseinpanah F., Azizi F. The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in Southwest of Iran. Reprod Biol Endocrinol. 2014; 12: 89. DOI: 10.1186/1477-7827-12-89.
22. Sanchez N., Jones H. “Less Than A Wife”: A Study of Polycystic Ovary Syndrome Content in Teen and Women’s Digital Magazines. J Med Internet Res. 2016; 18 (6): e89. DOI: 10.2196/jmir.5417.
23. Abbott D.l-I., Bacha F. Ontogeny of Polycystic Ovary Syndrome and Insulin Resistance In Utero and Early Childhood. Fertil Steril. 2013; 100 (1): 2-11. DOI: 10.1016/j.fertnstert.2013.05.023.
24. De Leo V., Musacchio M., Cappelli V., Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14 (1): 38. DOI: 10.1186/s12958-016-0173-x.
25. Mikhailova S.V., Zykova T.A. Vitamin D, autoimmune thyroid diseases and reproductive disorders in women. [Vitamin D, autoimmunnye zabolevaniya shchitovidnoi zhelezy i narusheniya reproduktivnoi funktsii u zhenshchin]. Sibirskii meditsinskii zhurnal. 2013; 7: 13-8 (in Russian).
26. He C., Lin Z., Robb S.W., Ezeamama A.E.Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta¬Analysis. Nutrients. 2015; 7 (6): 4555-77.DOI: 10.3390/nu7064555.
27. Reyes-Mufloz E., Ortega-Gonzalez C., Martinez-Cruz N., Arce-Sanchez L., Estrada-Gutierrez G., Moran С., Sanchez-Serrano А.Р., Higareda-Sanchez R., de la Jara-Diaz J.F. Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinical- biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study. BMJ Open. 2016; 6 (7): e012107. DOI: 10.1136/bmjopen-2016-012107.
28. Dukhanina E.S., Khoroshikh N.V., Brigadirova V.Yu. Clinical features of polycystic ovary syndrome at the present stage. [Osobennosti klinicheskoi kartiny sindroma polikistoznykh yaichnikov na sovremennom etape]. Byulleten' meditsinskikh internet-konferentsii. 2015; 5 (12): 1459-60 (in Russian).
29. Dubinskaya E.D., Gasparov A.S., Fedorova T.A., Lapteva N.V. The role of genetic factors, detoxification systems and oxidative stress in endometriosis and infertility (literature review). [Rol' geneticheskikh faktorov, sistemy detoksikatsii i oksidativnog stressa pri endometrioze i besplodii (obzor literatury)]. Vestnik RAMN. 2013; 8: 14-9 (in Russian).
30. Guo R., Zheng Y., Yang J., Zheng N. Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. BMC Genet. 2015; 16(1): 5. DOI: 10.1186/s12863-015-0165-4.
31. Rosenfield R.L. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum. JPediatr Adolesc Gynecol. 2015; 28 (6): 412-19. DOI: 10.1016/j.jpag.2014.07.016.
32. Pisareva E.V., Razumnaya A.E., Borzenkova A.V. Studies of hormonal status of women with various disorders of the reproductive function. [Issledovaniya gormonal'nogo statusa zhenshchin s razlichnymi narusheniyami reproduktivnoi funktsii]. Vestnik SamGU. Estestvennonauchnaya seriya. 2013; 9/1 (110): 191-7 (in Russian).
33. Dokras A. Cardiovascular Disease Risk in Women with PCOS. Steroids. 2013; 78 (8): 773-6.
34. Zenkina V.G. Angiogenesis factors in the development of physiological and pathological processes of female gonads. [Faktory angiogeneza pri razvitii fiziologicheskikh i patologicheskikh protsessov zhenskoi gonady]. Byulleten' sibirskoi meditsiny. 2016; 15 (4): 111-9 (in Russian).
35. Dube R. Does endothelial dysfunction correlate with endocrinal abnormalities in patients with polycystic ovary syndrome? Avicenna J Med. 2016; 6 (4): 91-102. DOI: 10.4103/2231-0770.191445.
36. Pavlova T.V., Kulikovskii V.F., Pavlova L.A. Clinical and Experimental Morphology [Klinicheskaya i eksperimental'naya morfologiya]. Moskva: MIA, 2016. 256 s.
37. Povzun S.A. General pathological anatomy. [Obshchaya patologicheskay anatomiya]. Spb.: SpetsLit, 2015. 319 s (in Russian).
38. Dumesic D.A., Goodarzi М.О., Chazenbalk G.D., Abbottet D.H. Intrauterine Environment and PCOS. Semin Reprod Med. 2014; 32 (3): 159-65. DOI: 10.1055/s-0034-1371087.
39. McAllister JM, Legro R.S., Modi B.P., Strauss J.F. Functional Genomics of PCOS: From GWAS to Molecular Mechanisms. Trends Endocrinol Metab. 2015; 26 (3): 118-24. DOI: 10.1016/j.tem.2014.12.004.
40. Legro R.S., Gnatuk C.L., Kunselman A.R., Dunaif A. Changes in glucose tolerance over time in woman with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 90 (6): 3236-42.
41. Mironova M.P. Modern tactics of infertility therapy associated with polycystic ovary syndrome [Sovremennaya taktika terapii besplodiya, assotsiirovannogo s sindromom polikistoznykh yaichnikov]. Meditsinskii vestnik Bashkortostana. 2013; 6: 113-6 (in Russian).
42. Soboleva E.L., Potin V.V., Tarasova M.A. Treatment of androgen-dependent dermopathy. [Lechenie androgenzavisimoi dermopatii]. Zhurnal akusherstva i zhenskikh boleznei. 2010; 59 (2): 34-6 (in Russian).
43. Gavrailova D. Diabetes type 2 and polycystic ovary syndrome (PCOS) [Diabet 2-go tipa i sindrom polikistoznykh yaichnikov (SPKYa)]. Vestnik po pedagogike i psikhologii Yuzhnoi Sibiri. 2014; 3: 60-73 (in Russian).
44. Bachanek M., Abdalla N., Cendrowski K., Sawicki W. Value of ultrasonography in the diagnosis of polycystic ovary syndrome - literature review. J Ultrason. 2015; 15 (63): 410-22. DOI: 10.15557/JoU.2015.0038.
45. Kenigsberg Lf, Agarwal C., Sin S., Shifteh K., Isasi C.R., Crespi R., Ivanova J., Coupey S.M., Heptulla R.A., Arens R. Clinical Utility of Magnetic Resonance Imaging (MRI) and Ultrasonography (US) for Diagnosis of Polycystic Ovary Syndrome (PCOS) in Adolescent Girls. Fertil Steril. 2015; 104 (5): 1302-9. е1-4. DOI: 10.1016/j.fertnstert.2015.08.002.
46. Brown M., Park A.S., Shayya R.F., Wolfson T., Su H.I., Chang R.J. Ovarian Imaging by Magnetic Resonance in Adolescent Girls with Polycystic Ovary Syndrome and Age-Matched Controls. J Magn Reson Imaging. 2013; 38 (3): 689-93. DOI: 10.1002/jmri.23992.
47. Bargiota A., Diamanti-Kendarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab. 2012; 3 (1): 27-47.
48. Falbo A., Rocca M., Russo T., D'Ettore A., Tolino A., Zullo F., Orio F., Palomba S. Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes. J Ovarian Res. 2010; 3 (1): 23. DOI: 10.1186/1757-2215-3-23.
49. Diamanti-Kandarakis E., Piperi C., Patsouris E., Korkolopoulou P, Panidis D., Pawelczyk L., Papavassiliou A.G., Duleba A.J. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol. 2007; 127 (6): 581-9.
50. Mitra S., Nayak P.K., Agrawal S. Laparoscopic ovarian drilling: An alternative but not the ultimate in the management of polycystic ovary syndrome. J Nat Sci Biol Med. 2015; 6 (1): 40-8. DOI: 10.4103/0976-9668.149076.
51. Kong W., Niu X., Zeng T., Lu M., Chen L. Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis. PLoS One. 2015; 10 (10): e0140565. DOI: 10.1371/journal.pone.0140565.
52. Arentz S., Abbott J.A, Smith C.A., Bensoussan A. Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings. BMC Complement Altern Med. 2014; 14: 511. DOI: 10.1186/1472-6882-14-511.
53. Rojas J., Chavez M., Olivar L., Morillo J., Mejias J. Polycystic Ovary Syndrome, Insulin Resistance, and Obesity: Navigating the Pathophysiologic Labyrinth. Int J Reprod Med. 2014; 2014: 719050. DOI: 10.1155/2014/719050.
54. Yang Y.M., Choi E.J. Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome. Ther Clin Risk Manag. 2015; 11: 1345-53. DOI: 10.2147/TCRM.S89737.
55. Evert L.S., Galonskii V.G., Tepper E.A., Volynkina A.I., Tarasova N.V. Pregnancy outcomes and health status of children born after assisted reproductive technology. [Iskhody beremennosti i sostoyanie zdorov'ya detei, rozhdennykh posle primeneniya vspomogatel'nykh reproduktivnykh tekhnologii]. Sibirskii meditsinskii zhurnal (Tomsk). 2013; 28 (1): 65-9 (in Russian).
56. Maksimova Zh.V., Maksimov D.M. Screening: a modern view on the early diagnosis and prophylaxis of chronic noncommunicable diseases. [Skrining: sovremennyi vzglyad na rannyuyu diagnostiku i profilaktiku khronicheskikh neinfektsionnykh zabolevanii]. Arkhiv vnutrennei meditsiny. 2014; 6 (20): 52-6 (in Russian).
57. Comim F.V., Hardy K., Franks S. Adiponectin and Its Receptors in the Ovary: Further Evidence for a Link between Obesity and Hyperandrogenism in Polycystic Ovary Syndrome. PLoS One. 2013; 8 (11): e80416. DOI: 10.1371/journal.pone.0080416.
58. Gao T., Wu L., Chang F., Cao G. Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and metaanalysis. Endocr J. 2016; 63 (1): 93-100. DOI: 10.1507/endocrj.EJ15-0318.
59. Tessaro I., Modina S.C., Franciosi F., Sivelli G., Terzaghi L., Lodde V., Luciano A.M. Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome. J Ovarian Res. 2015; 8 (1): 64. DOI: 10.1186/s13048-015-0192-9.
60. Dumont A., Robin G., Catteau-Jonard C., Dewailly D. Role of Anti-Mullerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review. Reprod Biol Endocrinol. 2015; 13: 137. DOI: 10.1186/s12958-015-0134-9.
61. Singh AX., Singh R. Can anti-Mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. Indian J Endocrinol Metab. 2015; 19 (6): 731-43. DOI: 10.4103/2230-8210.167548.
Review
For citations:
Solopova A.G., Makatsariya A.D., Solopova A.E., Nikiforova O.V. SCLEROCYSTIC OVARIES: CURRENT APPROACHES TO THE PROBLEM. Obstetrics, Gynecology and Reproduction. 2017;11(2):57-68. (In Russ.) https://doi.org/10.17749/2313-7347.2017.11.2.057-068
Views:
1311
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
